Logo image of TRDA

ENTRADA THERAPEUTICS INC (TRDA) Stock Fundamental Analysis

NASDAQ:TRDA - Nasdaq - US29384C1080 - Common Stock - Currency: USD

5.8  -0.08 (-1.36%)

Fundamental Rating

4

TRDA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. TRDA has an excellent financial health rating, but there are some minor concerns on its profitability. TRDA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

TRDA had positive earnings in the past year.
TRDA had a negative operating cash flow in the past year.
In the past 5 years TRDA reported 4 times negative net income.
TRDA had negative operating cash flow in 4 of the past 5 years.
TRDA Yearly Net Income VS EBIT VS OCF VS FCFTRDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

With an excellent Return On Assets value of 5.09%, TRDA belongs to the best of the industry, outperforming 92.04% of the companies in the same industry.
Looking at the Return On Equity, with a value of 5.94%, TRDA belongs to the top of the industry, outperforming 92.95% of the companies in the same industry.
TRDA has a Return On Invested Capital of 0.69%. This is amongst the best in the industry. TRDA outperforms 91.68% of its industry peers.
Industry RankSector Rank
ROA 5.09%
ROE 5.94%
ROIC 0.69%
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
TRDA Yearly ROA, ROE, ROICTRDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

TRDA has a Profit Margin of 14.39%. This is amongst the best in the industry. TRDA outperforms 93.85% of its industry peers.
TRDA's Operating Margin of 2.39% is amongst the best of the industry. TRDA outperforms 92.22% of its industry peers.
Industry RankSector Rank
OM 2.39%
PM (TTM) 14.39%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRDA Yearly Profit, Operating, Gross MarginsTRDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

8

2. Health

2.1 Basic Checks

TRDA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for TRDA has been increased compared to 1 year ago.
The number of shares outstanding for TRDA has been increased compared to 5 years ago.
There is no outstanding debt for TRDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TRDA Yearly Shares OutstandingTRDA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
TRDA Yearly Total Debt VS Total AssetsTRDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 2.84 indicates that TRDA is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of TRDA (2.84) is better than 73.06% of its industry peers.
TRDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.84
ROIC/WACC0.08
WACC9.04%
TRDA Yearly LT Debt VS Equity VS FCFTRDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 21.88 indicates that TRDA has no problem at all paying its short term obligations.
The Current ratio of TRDA (21.88) is better than 94.76% of its industry peers.
A Quick Ratio of 21.88 indicates that TRDA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 21.88, TRDA belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 21.88
Quick Ratio 21.88
TRDA Yearly Current Assets VS Current LiabilitesTRDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

TRDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.57%, which is quite impressive.
TRDA shows a small growth in Revenue. In the last year, the Revenue has grown by 5.74%.
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.76%
Revenue 1Y (TTM)5.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-65.23%

3.2 Future

TRDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.13% yearly.
TRDA is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-268.89%
EPS Next 2Y-106.63%
EPS Next 3Y-59.93%
EPS Next 5Y34.13%
Revenue Next Year-74.92%
Revenue Next 2Y-57.53%
Revenue Next 3Y-32.87%
Revenue Next 5Y-14.87%

3.3 Evolution

TRDA Yearly Revenue VS EstimatesTRDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2030 50M 100M 150M 200M
TRDA Yearly EPS VS EstimatesTRDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 5 -5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

TRDA is valuated cheaply with a Price/Earnings ratio of 7.16.
Based on the Price/Earnings ratio, TRDA is valued cheaper than 98.37% of the companies in the same industry.
TRDA's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.82.
The Forward Price/Earnings Ratio is negative for TRDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 7.16
Fwd PE N/A
TRDA Price Earnings VS Forward Price EarningsTRDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -60.06
TRDA Per share dataTRDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as TRDA's earnings are expected to decrease with -59.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-106.63%
EPS Next 3Y-59.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTRADA THERAPEUTICS INC

NASDAQ:TRDA (8/1/2025, 8:07:04 PM)

5.8

-0.08 (-1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners78.07%
Inst Owner Change0.08%
Ins Owners0.79%
Ins Owner Change3.37%
Market Cap220.11M
Analysts84
Price Target20.91 (260.52%)
Short Float %3.99%
Short Ratio9.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.1%
Min EPS beat(2)47.81%
Max EPS beat(2)104.39%
EPS beat(4)4
Avg EPS beat(4)288.27%
Min EPS beat(4)47.81%
Max EPS beat(4)948.01%
EPS beat(8)6
Avg EPS beat(8)190.15%
EPS beat(12)7
Avg EPS beat(12)116.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)138.81%
Min Revenue beat(2)98.17%
Max Revenue beat(2)179.44%
Revenue beat(4)4
Avg Revenue beat(4)108.71%
Min Revenue beat(4)55.73%
Max Revenue beat(4)179.44%
Revenue beat(8)8
Avg Revenue beat(8)153%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-15.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.1%
EPS NY rev (1m)0%
EPS NY rev (3m)7.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.22%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)27.53%
Valuation
Industry RankSector Rank
PE 7.16
Fwd PE N/A
P/S 1.28
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA -60.06
EPS(TTM)0.81
EY13.97%
EPS(NY)-4.33
Fwd EYN/A
FCF(TTM)-1.53
FCFYN/A
OCF(TTM)-1.44
OCFYN/A
SpS4.54
BVpS10.99
TBVpS11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.09%
ROE 5.94%
ROCE 0.88%
ROIC 0.69%
ROICexc 3.79%
ROICexgc 3.79%
OM 2.39%
PM (TTM) 14.39%
GM N/A
FCFM N/A
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 91.52%
Cap/Sales 2.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.88
Quick Ratio 21.88
Altman-Z 2.84
F-Score5
WACC9.04%
ROIC/WACC0.08
Cap/Depr(3y)144.47%
Cap/Depr(5y)309.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.76%
EPS Next Y-268.89%
EPS Next 2Y-106.63%
EPS Next 3Y-59.93%
EPS Next 5Y34.13%
Revenue 1Y (TTM)5.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-65.23%
Revenue Next Year-74.92%
Revenue Next 2Y-57.53%
Revenue Next 3Y-32.87%
Revenue Next 5Y-14.87%
EBIT growth 1Y-82.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-736.79%
EBIT Next 3Y-107.2%
EBIT Next 5YN/A
FCF growth 1Y-145.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-141.76%
OCF growth 3YN/A
OCF growth 5YN/A